Cargando…

Retinal Vein Occlusion in a Patient on Dabrafenib and Trametinib Therapy for Metastatic Melanoma

The purpose of this case report is to highlight the ocular complications of dabrafenib and trametinib treatment. We discuss the case of an 81-year-old female treated with dabrafenib and trametinib for metastatic melanoma, who developed a retinal branch vein occlusion with macular edema in the right...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molero-Senosiain, Mercedes, Salazar, Maria Liseth, Camacho, Irene, Benito-Pascual, Blanca, Valor-Suarez, Clara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Dermatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508681/ https://www.ncbi.nlm.nih.gov/pubmed/36171851 http://dx.doi.org/10.7759/cureus.28372

Ejemplares similares

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Primary Melanoma of the Lung Treated with Surgery, Dabrafenib and Trametinib
por: Landgraf, Layla G., et al.
Publicado: (2020)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015)

Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib
por: Draganova, Dafina, et al.
Publicado: (2015)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023)

Ocular toxicity due to Trametinib and Dabrafenib
por: Sarny, Stephanie, et al.
Publicado: (2017)

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy
por: Luke, Jason J, et al.
Publicado: (2014)

Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: Case report
por: Sundaram, Vinita Ruth, et al.
Publicado: (2018)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
por: Shalata, Walid, et al.
Publicado: (2023)

Dabrafenib/trametinib: Cardiac toxicity: case report
Publicado: (2021)

A Case of Intracranial Hemorrhage Caused by Combined Dabrafenib and Trametinib Therapy for Metastatic Melanoma
por: Lee, Le Min, et al.
Publicado: (2014)

Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma
por: Laino, Antonia, et al.
Publicado: (2018)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
por: Balakirouchenane, David, et al.
Publicado: (2020)

Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature
por: Garrett, Giorgia L., et al.
Publicado: (2015)

Delphi panel for consensus on the optimal management of dabrafenib plus trametinib-related pyrexia in patients with melanoma
por: Frazer, Ricky, et al.
Publicado: (2022)

Effectiveness Treatment of a BRAF-ZKSCAN5 Fusion Gene Melanoma Case with Dabrafenib/Trametinib
por: Kato, Hiroshi, et al.
Publicado: (2023)

Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
por: Chapman, Paul B., et al.
Publicado: (2023)

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
por: Minor, David R., et al.
Publicado: (2015)

Dabrafenib- and trametinib-associated glomerular toxicity: A case report
por: Jo, Eunmi, et al.
Publicado: (2022)

Ocular side effects of Trametinib and Dabrafenib: a case report
por: Tarım, Bilge, et al.
Publicado: (2023)

Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma
por: Mistry, Hitesh B., et al.
Publicado: (2017)

A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy
por: Mormando, Marilda, et al.
Publicado: (2020)

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
por: Brase, Jan C., et al.
Publicado: (2021)

Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
por: Isberner, Nora, et al.
Publicado: (2022)

Correlation Between Retrograde Trans-Synaptic Degeneration of Ganglion Cells and Optical Coherence Tomography Angiography Following Ischemic Stroke
por: Molero-Senosiain, Mercedes, et al.
Publicado: (2021)

Dabrafenib and Trametinib Treatment for Erdheim-Chester Disease With Brain Stem Involvement
por: Al Bayati, Ahmed, et al.
Publicado: (2018)

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements
por: Thawer, Alia, et al.
Publicado: (2021)

Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study
por: Martín Algarra, Salvador, et al.
Publicado: (2017)

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
por: Ganguly, Sandip, et al.
Publicado: (2021)

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
por: Atkinson, Victoria G., et al.
Publicado: (2021)

Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience
por: Bueno, Fernanda, et al.
Publicado: (2023)

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
por: Daud, Adil, et al.
Publicado: (2017)

Acute granulomatous interstitial nephritis in a patient with metastatic melanoma on targeted therapy with dabrafenib and trametinib—A case report
por: Krelle, Anna, et al.
Publicado: (2021)

Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study
por: Manzano, José L., et al.
Publicado: (2023)

Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
por: Weart, Thomas C, et al.
Publicado: (2018)

Guillain-Barre Syndrome Secondary to the Use of Dabrafenib and Trametinib for the Treatment of Advanced Thyroid Carcinoma
por: Batra, Jaskaran, et al.
Publicado: (2023)

Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAF(v600e) mutated melanoma cells in vitro
por: Scatena, Cristian, et al.
Publicado: (2019)

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
por: Dummer, Reinhard, et al.
Publicado: (2022)

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
por: Long, G. V., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_32ueck8ea88al5j7g7vjjglivt